Portfolio Lab

Kiniksa Pharmaceuticals International, plc

  • Stock
  • Ticker KNSA
  • Nasdaq

Health care · Pharmaceuticals · USA

$93.90 +0.38%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Kiniksa Pharmaceuticals International, plc since 05/2018, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

KNSAGlobal equities (VT)

$10,000 grew to $90,371. Global equities (VT): $14,653.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −83.1% in 10/2019, measured from the peak in 09/2018. It took 82 months to get back to the old peak.

1-year return
+126.3%
5-year return p.a.
+50.4%
Return p.a. since 05/2018
+20.4%
Volatility p.a.
59.3%
Largest decline
−83.1%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue123138157181202214244286
Gross profit105120138161181193220258
Operating income-1913202420292754
EBITDA-1914202420302754
Net income-8.98.5181814232547
Earnings per share-0.120.110.230.230.180.270.300.56
Balance sheet
Total assets581599661712764825896983
Liabilities142142166177196220242273
Equity438457495535568606654710
Cash18415719217516619017682
Cash flow
Operating cash flow1922283454504748
Capital expenditure-0.2-0.1-0.2-0.7-0.6-0.2-0.7-0.2
Free cash flow1922283353504747

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2025 at +108.5%, weakest 2019 at −60.6%. 5 of 7 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
27 Oct 2026$0.56
28 Jul 2026$0.30
28 Apr 2026$0.27
24 Feb 2026$0.18
28 Oct 2025$0.23
29 Jul 2025$0.23
29 Apr 2025$0.11
25 Feb 2025−$0.12
29 Oct 2024−$0.18
25 Jul 2024−$0.06
25 Apr 2024−$0.25
28 Feb 2024$0.36

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€7.2bn
Market cap in trading currency
$7.97bn
Enterprise value
$7.40bn
P/E
71.7
P/S
8.43
P/B
11.23
EV/Sales
7.83
EV/EBITDA
56.2
Earnings yield
1.4%
FCF yield
2.5%

Results (last four quarters)

Revenue
$946m
Gross profit
$853m
EBITDA
$132m
Net income
$110m
Earnings per share
$1.31
Revenue per share
$11.14
Revenue growth
+58.1%
Earnings growth
+156.8%

Profitability

Gross margin
90.2%
Operating margin
13.8%
Net margin
11.6%
Return on equity
17.6%
Return on assets
11.1%

Balance sheet and cash flow

Cash
$569m
Cash per share
$6.70
Financial debt
–
Debt/equity %
–
Current ratio
3.91
Book value per share
$8.36
Operating cash flow
$199m
Free cash flow
$197m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
84.9m
Volume
544,863
Avg. volume 3 months
673,868
Relative volume
0.8

Price and technicals

Price
$93.90
1 day
+0.4%
52-week high
$98.76
52-week low
$37.92
Distance to 52-week high
−4.9%
Distance to 52-week low
+147.6%
Distance to 50-day line
+11.9%
Distance to 200-day line
+46.5%
RSI (14)
56
Volatility 1M
93.9%

Performance

1 week
−2.5%
1 month
+16.2%
3 months
+18.3%
6 months
+76.4%
YTD
+127.6%
1 year
+122.7%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has KNSA performed since 05/2018?

$10,000 grew to $48,225 by 20 Nov 2026, which is +20.4% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is KNSA?

Volatility was 59.3% per year, measured on monthly returns. The largest decline from a peak was −83.1%, with the low in 10/2019.

How does KNSA compare with a broad equity ETF?

Over the same period Global equities (VT) returned +10.0% per year at 16.1% volatility, KNSA returned +20.4% at 59.3%. The correlation of monthly returns was 0.03; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Kiniksa Pharmaceuticals International, plc (KNSA)